Equities research analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to announce sales of $14.04 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Inovio Pharmaceuticals’ earnings. The highest sales estimate is $20.87 million and the lowest is $7.20 million. Inovio Pharmaceuticals posted sales of $12.54 million in the same quarter last year, which suggests a positive year-over-year growth rate of 12%. The firm is scheduled to announce its next earnings results after the market closes on Wednesday, November 8th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year sales of $14.04 million for the current fiscal year, with estimates ranging from $41.80 million to $72.61 million. For the next financial year, analysts forecast that the firm will post sales of $32.52 million per share, with estimates ranging from $28.80 million to $36.23 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The firm had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. Inovio Pharmaceuticals’s quarterly revenue was up 229.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) EPS.

Several brokerages have recently commented on INO. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. Finally, Royal Bank Of Canada began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $19.16.

Institutional investors have recently added to or reduced their stakes in the business. BlueCrest Capital Management Ltd acquired a new position in Inovio Pharmaceuticals during the 2nd quarter valued at about $107,000. Emerald Advisers Inc. PA lifted its position in Inovio Pharmaceuticals by 84.0% during the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 9,280 shares during the period. PNC Financial Services Group Inc. lifted its position in Inovio Pharmaceuticals by 5.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in Inovio Pharmaceuticals during the 2nd quarter valued at about $171,000. Finally, OxFORD Asset Management LLP acquired a new position in Inovio Pharmaceuticals during the 2nd quarter valued at about $194,000. Institutional investors own 25.02% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/02/inovio-pharmaceuticals-inc-ino-expected-to-post-quarterly-sales-of-14-04-million.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.